labquiet_amy said:

Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…

I would rather people stopped quoting the 24% as if it were a licensed outcome. It is a phase 2 result in a few hundred participants with no cardiovascular endpoint and no long-term safety data, and this board has a habit of treating pipeline numbers as settled.

Adding the numbers, since they settle part of this. Worth stating the units and the reference range whenever you post a number here. A large fraction of the apparent disagreement in these threads is two people using different units and both being right.

BariatricNurseD said:

I would rather people stopped quoting the 24% as if it were a licensed outcome.

There is a second half to this that has not been said yet. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.

Happy to go further on any of that.

Following on from A1cHero_PHX — and this may be the naive question:

Why adding glucagon agonism to an anti-obesity drug is not self-defeating, given that glucagon raises blood glucose?

Closing the loop on my own question.

Rereading it with the dropout table open changed my view. I still think it is the most interesting molecule in the pipeline; I no longer think the 24% is the number that will end up on a label.